Journal Mobile Options
Table of Contents
Vol. 78, No. 2, 2007
Issue release date: February 2007
Urol Int 2007;78:140–144
(DOI:10.1159/000098072)

Significance of Collagenase 3 (Matrix Metalloproteinase 13) in Invasive Bladder Cancer: Correlation with Pathological Parameters

Rodríguez Faba O. · Fernández Gómez J.M. · Palou Redorta J. · Escaf Barmadah S. · Vizoso F. · Villavicencio Mavrich H.
aDepartment of Urology and Pathology, University of Oviedo, Oviedo, bDepartment of Urology, Fundació Puigvert, Barcelona, and cDepartment of Surgery, Hospital of Jove, Gijón, Spain

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Purpose: To determine if collagenase 3 expression is associated with stage progression and prognosis of bladder cancer. Patients and Methods: Immunohistochemical staining for collagenase 3 was carried out on serial sections from specimens of 42 patients (32 males and 10 females) who underwent radical cystectomy for bladder cancer (median follow-up, 67.2 ± 5.99 months). Results: Immunohistochemical expression of collagenase 3 was detected in 13 (31%) patients. Pathological stage was pT2 in 12 (28.57%) patients, pT3a in 7 (16.6%), pT3b in 21 (50%) and pT4 in 2 (4.76%). Four tumours (9.52%) were grade II and 38 (90.47%) were grade III. Stage and tumours >3 cm in size were associated with bladder cancer progression-free survival and overall survival. We did not find any statistical differences with collagenase 3 expression related with stage and size. Conclusions: Immunohistochemical expression of matrix metalloproteinase 13 in invasive bladder cancer is not useful as marker for transformation and invasion. These findings should be evaluated in large multicentre prospective trials.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Brinckerhoff CE, Matrisian LM: Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002;3:207–214.
  2. Puente X, Sanchez LM, Overall CM, López-Otín C: Human and mouse proteases: a comparative genomic approach. Nat Rev Genet 2003;4:544–558.
  3. Uria JA, López-Otín C: Matrilysin-2, a new matrix metalloproteinase expressed in human tumours and showing the minimal domain organization required for secretion, latency and activity. Cancer Res 2000;60:4745–4751.
  4. Folgueras AR, Pendás AM, Sánchez LM, López-Otín C: Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 2004;48:411–424.
  5. Epstein J, Amin M, Reuter V, Motoffi F: The world health organisation/international society of urological pathology consensus classification of urothelial neoplasms of the urinary bladder. Am J Surg Pathol 1998;22:1435–1448.
  6. Bostrom PJ, Ravanti L, Reunanen N: Expression of collagenase-3 (matrix metalloproteinase-13) in transitional-cell carcinoma of the urinary bladder. Int J Cancer 2000;88:417–423.
  7. Hattori M, Ohno E, Kuramoto H: Immunocytochemistry of collagenase expression in transitional cell carcinoma of the bladder. Acta Cytol 2000;44:771–777.
  8. Manes S, Mira E, Barbacid M, et al: Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem 1997;272:25706–25712.
  9. Yu C, Pan K, Xing D, et al: Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res 2002;62:6430–6433.
  10. Balbin M, Fueyo A, Knauper V, et al: Collagenase-2 (MMP-8) expression in murine tissue-remodeling processes: analysis of its potential role in postpartum involution of the uterus. J Biol Chem 1998;273:23959–23968.
  11. Johanson N, Airola K, Grenman R: Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 1997;151:499–508.

    External Resources

  12. Airola K, Johansson N, Kariniemi A, et al: Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J Invest Dermatol 1997;109:225–231.
  13. Uria JA, Balbin M, López JM: Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor. Am J Pathol 1998;153:91–101.
  14. Nielsen BS, Rank F, López JM, et al: Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. Cancer Res 2001;61:7091–7100.
  15. Nielsen BS, Rank F, López JM, et al: Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. Cancer Res 2001;61:7091–7100.
  16. Dalbagni G, Genega E, Hashibe M: Cystectomy for bladder cancer: a contemporary series. J Urol 2001;165:1111–1116.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50